Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomised controlled trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kumar, 2009, Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock, Chest, 136, 1237, 10.1378/chest.09-0087
Gradel, 2017, Impact of appropriate empirical antibiotic treatment on recurrence and mortality in patients with bacteraemia: a population-based cohort study, BMC Infect Dis, 17, 122, 10.1186/s12879-017-2233-z
Battle, 2017, Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis, J Antimicrob Chemother, 72, 299, 10.1093/jac/dkw402
Chen, 2020, Comparisons of clinical features and outcomes between Elizabethkingia meningoseptica and other glucose non-fermenting Gram-negative bacilli bacteremia in adult ICU patients, J Microbiol Immunol Infect, 53, 344, 10.1016/j.jmii.2018.08.016
Su, 2020, Ignorance of pre-ED healthcare setting is a factor leading to inappropriate initial antibiotic treatment of sepsis in ED and poor outcomes in ICU, J Microbiol Immunol Infect, 53, 532, 10.1016/j.jmii.2019.11.001
Bassetti, 2020, Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections, Int J Antimicrob Agents, 56, 106184, 10.1016/j.ijantimicag.2020.106184
Chusri, 2019, Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia, J Microbiol Immunol Infect, 52, 796, 10.1016/j.jmii.2019.03.004
US Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States; 2019. https://www.cdc.gov/drugresistance/biggest-threats.html [accessed 30.10.20].
Abdul-Mutakabbir, 2020, Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant Gram-negative pathogens, Pharmacotherapy, 40, 1228, 10.1002/phar.2476
Chen, 2019, Comparative in vivo antibacterial activity of human-simulated exposures of cefiderocol and ceftazidime against Stenotrophomonas maltophilia in the murine thigh model, Antimicrob Agents Chemother, 63, e01558, 10.1128/AAC.01558-19
Delgado-Valverde, 2020, Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia, J Antimicrob Chemother, 75, 1840, 10.1093/jac/dkaa117
Karlowsky, 2019, In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015, Int J Antimicrob Agents, 53, 456, 10.1016/j.ijantimicag.2018.11.007
Kresken, 2020, In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany, Int J Antimicrob Agents, 56, 106128, 10.1016/j.ijantimicag.2020.106128
Mushtaq, 2020, In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant Gram-negative bacteria, Antimicrob Agents Chemother, 64, e01582, 10.1128/AAC.01582-20
Trebosc, 2020, In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms, J Antimicrob Chemother, 75, 3552, 10.1093/jac/dkaa370
Alamarat, 2020, Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-β-lactamase-producing Klebsiella pneumoniae in a pediatric patient, Antimicrob Agents Chemother, 64, e01872, 10.1128/AAC.01872-19
Edgeworth, 2019, Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to extremely drug-resistant Pseudomonas aeruginosa, Clin Infect Dis, 68, 1932, 10.1093/cid/ciy963
Kufel, 2020, Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: clinical observations and susceptibility testing considerations, IDCases, 21, e00863, 10.1016/j.idcr.2020.e00863
Oliva, 2020, Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii, J Glob Antimicrob Resist, 23, 292, 10.1016/j.jgar.2020.09.019
Siméon, 2020, Compassionate use of cefiderocol to treat a case of prosthetic joint infection due to extensively drug-resistant Enterobacter hormaechei, Microorganisms, 8, 1236, 10.3390/microorganisms8081236
Stevens, 2019, Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug-resistant Pseudomonas aeruginosa: a case report, Pharmacotherapy, 39, 1113, 10.1002/phar.2334
Trecarichi, 2019, Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report, J Antimicrob Chemother, 74, 3399, 10.1093/jac/dkz318
Portsmouth, 2018, Cefiderocol versus imipenem–cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial, Lancet Infect Dis, 18, 1319, 10.1016/S1473-3099(18)30554-1
Wunderink, 2021, Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial, Lancet Infect Dis, 21, 213, 10.1016/S1473-3099(20)30731-3
Bassetti, 2021, Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect Dis, 21, 226, 10.1016/S1473-3099(20)30796-9
Shamseer, 2015, PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015, elaboration and explanation, BMJ, 350, g7647, 10.1136/bmj.g7647
Higgins, 2011, The Cochrane Collabaration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928
Hackel, 2017, In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study), Antimicrob Agents Chemother, 61, e00093, 10.1128/AAC.00093-17
Kohira, 2016, In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacterales clinical isolates, including carbapenem-resistant strains, Antimicrob Agents Chemother, 60, 729, 10.1128/AAC.01695-15
Hackel, 2018, In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016, Antimicrob Agents Chemother, 62, e01968, 10.1128/AAC.01968-17